Document Detail


CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer.
MedLine Citation:
PMID:  23059958     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer. METHODS: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA. RESULTS: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status. CONCLUSIONS: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values. Prostate © 2012 Wiley Periodicals, Inc.
Authors:
Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Related Documents :
20548938 - Anticancer and antiradical scavenging activity of ageratum conyzoides l. (asteraceae).
18239318 - Withangulatin i, a new cytotoxic withanolide from physalis angulata.
19648968 - Lmo4 is an essential mediator of erbb2/her2/neu-induced breast cancer cell cycle progre...
19373868 - Inhibition of relb by 1,25-dihydroxyvitamin d3 promotes sensitivity of breast cancer ce...
22269078 - Transition to breast cancer survivorship: a longitudinal qualitative follow-up study of...
21711998 - Neuroendocrine carcinoma of breast.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  The Prostate     Volume:  -     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Department of Urology, The University of Michigan School of Medicine, Ann Arbor, Michigan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ternary Donor-Insulator-Acceptor Systems for Polymer Solar Cells.
Next Document:  Predictors of bloodstream infection associated with permanently implantable venous port in solid can...